Board of Directors

Brian Bloom, Chairman of the Board

Mr. Brian Bloom, a co-founder of Bloom Burton & Co., serves as the firm’s Chairman and Chief Executive Officer and specializes in serving investors looking to the international healthcare community. Mr. Bloom serves as Chairman of the Board of Directors of Appili Therapeutics and Grey Wolf Animal Health, and is a member of the Life Sciences Advisory Board of the National Research Council of Canada, as well as a member of the Board of Directors at BIOTECanada, the Baycrest Foundation, and Qing Bile Therapeutics. Before co-founding Bloom Burton in 2008, Mr. Bloom spent six years at Dundee Securities in the healthcare and biotechnology institutional sales and equity research groups. He started his career at New York-based investment banking firms SCO Financial Group and Molecular Securities. Mr. Bloom received an HBSc in Biochemistry from McMaster University and subsequently studied at the Mount Sinai Graduate School for Biological Sciences of New York University, with a focus in molecular endocrinology and biophysics.

Jonathan Bramson, PhD

Dr. Jonathan Bramson founded Triumvira Immunologics, Inc., along with his post-doctoral Fellow, Dr. Christopher Helsen, in 2015. He is currently a Professor in the Department of Pathology and Molecular Medicine and the Vice Dean (Research) for the Faculty of Health Sciences at McMaster University. He holds a Tier I Canada Research Chair in Translational Cancer Immunology and the John Bienestock Chair in Molecular Medicine. As an immunologist who has been researching novel cancer immune-oncology strategies since 1994, Dr. Bramson’s lab is focused on developing methods to direct cancer patients’ immune systems to attack their tumors. To this end, the lab has been developing novel methods to engineer T cells to attack cancer and designing vaccines based on recombinant viruses to boost immunity against specific tumor antigens. The Bramson lab works closely with clinical partners at the Juravinski Hospital in Hamilton to optimally develop these exciting new immune strategies to address unmet needs within the cancer community in Southern Ontario. Together, Dr. Bramson and his colleagues have established an infrastructure at McMaster, which includes GMP production and GLP correlative assays, for conducting clinical trials of novel immune-oncology therapies that is unparalleled in Canada. Dr. Bramson received his PhD in Experimental Medicine in 1994 from McGill University.

Jonathan Bramson, PhD

Dr. Jonathan Bramson founded Triumvira Immunologics, Inc., along with his post-doctoral Fellow, Dr. Christopher Helsen, in 2015. He is currently a Professor in the Department of Pathology and Molecular Medicine and the Vice Dean (Research) for the Faculty of Health Sciences at McMaster University. He holds a Tier I Canada Research Chair in Translational Cancer Immunology and the John Bienestock Chair in Molecular Medicine. As an immunologist who has been researching novel cancer immune-oncology strategies since 1994, Dr. Bramson’s lab is focused on developing methods to direct cancer patients’ immune systems to attack their tumors. To this end, the lab has been developing novel methods to engineer T cells to attack cancer and designing vaccines based on recombinant viruses to boost immunity against specific tumor antigens. The Bramson lab works closely with clinical partners at the Juravinski Hospital in Hamilton to optimally develop these exciting new immune strategies to address unmet needs within the cancer community in Southern Ontario. Together, Dr. Bramson and his colleagues have established an infrastructure at McMaster, which includes GMP production and GLP correlative assays, for conducting clinical trials of novel immune-oncology therapies that is unparalleled in Canada. Dr. Bramson received his PhD in Experimental Medicine in 1994 from McGill University.

Cynthia (Cindy) Collins, MBA

Ms. Collins was the CEO of Human Longevity, Inc., the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. Prior to her time at Human Longevity, Inc., Ms. Collins was CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clarient Diagnostics. She was also the President and CEO of GenVec, Inc., and spent 17 years with Baxter Healthcare in a variety of executive roles, including President of Oncology, Vice President of Strategy and Portfolio Management of BioScience, Vice President & General Manager of Cell Therapies, and Vice President of Business Development of Transfusion Therapies. Ms. Collins is a member of the Board of Directors for the Analytical Life Science and Diagnostics Association, Alliance for Regenerative Medicine Foundation, and Cavidi AB, as well as serving as a strategic advisor to Phase Holographic Imaging. Ms. Collins received her BSc degree in Microbiology from the University of Illinois, Urbana, and her MBA from The University of Chicago Booth School of Business.

John Holyoake, PhD

Dr. John Holyoake, Vice President, Investment Banking, joined Bloom Burton & Co. in January 2012. Dr. Holyoake’s responsibilities include M&A advisory and monetization planning, as well as conducting technical and commercial due diligence of companies across all healthcare sectors. Dr. Holyoake’s area of expertise spans early-stage technologies to profitable healthcare service companies, with a focus on preclinical-stage biotech. He has previous industry experience with the clinical stage oncology company TenX BioPharma and the life science consulting group SHI Link, as well as with several early-stage life science companies. In addition to Triumvira, he currently serves on the Board of Directors of Appili Therapeutics, and is a member of the Core Evaluation Team for Genome Canada’s Genomic Applications Partnership Program and he also sits on the TOHealth Risk Capital Committee. Dr. Holyoake received his MSc in Biochemistry and PhD from the University of Oxford before coming to North America for a post-doctoral research fellowship at The Hospital for Sick Children, Toronto.

John Holyoake, PhD

Dr. John Holyoake, Vice President, Investment Banking, joined Bloom Burton & Co. in January 2012. Dr. Holyoake’s responsibilities include M&A advisory and monetization planning, as well as conducting technical and commercial due diligence of companies across all healthcare sectors. Dr. Holyoake’s area of expertise spans early-stage technologies to profitable healthcare service companies, with a focus on preclinical-stage biotech. He has previous industry experience with the clinical stage oncology company TenX BioPharma and the life science consulting group SHI Link, as well as with several early-stage life science companies. In addition to Triumvira, he currently serves on the Board of Directors of Appili Therapeutics, and is a member of the Core Evaluation Team for Genome Canada’s Genomic Applications Partnership Program and he also sits on the TOHealth Risk Capital Committee. Dr. Holyoake received his MSc in Biochemistry and PhD from the University of Oxford before coming to North America for a post-doctoral research fellowship at The Hospital for Sick Children, Toronto.

Dr. Zel Krajden, BSc, MD, FRCS(C)

Dr. Krajden is a Plastic & Reconstructive Surgeon who is the Chief of Surgery at Brampton Civic Hospital – in addition, he is the Division Head of Plastic Surgery at William Osler Health System. Dr. Krajden holds an academic appointment at McMaster University as an Assistant Clinical Professor (adjunct).

Dr. Krajden is the Past President of the Ontario Society of Plastic Surgeons as well as the Past Chair of the Plastic Surgery Section in the Ontario Medical Association. He has acted as the Plastic Surgery delegate at the Ontario Medical Association annual meeting and surgical assembly.

Dr. Krajden has been qualified as an expert witness in his specialty by the Ontario Superior Court of Justice as well as the Financial Services Commission of Ontario.

Paul Lammers, MD, MSc

Dr. Paul Lammers joined Triumvira Immunologics as President and Chief Executive Officer on January 1, 2018. In August 2017, he successfully completed a reverse merger of Mirna Therapeutics, the company for whom he served as Director, President, and CEO since 2009, with Synlogic of Cambridge, MA. During his tenure at Mirna Therapeutics, Dr. Lammers raised approximately $160 million in funding, both from Federal and State grants and leading traditional and strategic venture firms. He also brought the company public on the NASDAQ exchange. Previously, Dr. Lammers briefly served as President of Repros Therapeutics (NASDAQ: RPRX) in The Woodlands, Texas. Before Repros Therapeutics, he served 6 years as Chief Medical Officer and Head of US Product Development for EMD Serono Inc., a subsidiary of the German Pharmaceutical company, Merck KgA. Throughout his 30 years in the pharmaceutical and biotech industry, Dr. Lammers held different executive and senior management positions in clinical development, medical affairs, and regulatory affairs at both medium and large pharmaceutical companies, as well as at small public and privately held biotech companies. He started his pharmaceutical career at Organon in the Netherlands, after obtaining both a biology and medical degree, and moved with his family to the US in 1992. Dr. Lammers is a former member of the Board of the New England Healthcare Institute (NEHI) and former Chairman of the Board of BioSymposia, an accredited provider of CME programs for medical scientists and healthcare professionals. He currently serves on ImmunoMet’s Board of Directors.

Paul Lammers, MD, MSc

Dr. Paul Lammers joined Triumvira Immunologics as President and Chief Executive Officer on January 1, 2018. In August 2017, he successfully completed a reverse merger of Mirna Therapeutics, the company for whom he served as Director, President, and CEO since 2009, with Synlogic of Cambridge, MA. During his tenure at Mirna Therapeutics, Dr. Lammers raised approximately $160 million in funding, both from Federal and State grants and leading traditional and strategic venture firms. He also brought the company public on the NASDAQ exchange. Previously, Dr. Lammers briefly served as President of Repros Therapeutics (NASDAQ: RPRX) in The Woodlands, Texas. Before Repros Therapeutics, he served 6 years as Chief Medical Officer and Head of US Product Development for EMD Serono Inc., a subsidiary of the German Pharmaceutical company, Merck KgA. Throughout his 30 years in the pharmaceutical and biotech industry, Dr. Lammers held different executive and senior management positions in clinical development, medical affairs, and regulatory affairs at both medium and large pharmaceutical companies, as well as at small public and privately held biotech companies. He started his pharmaceutical career at Organon in the Netherlands, after obtaining both a biology and medical degree, and moved with his family to the US in 1992. Dr. Lammers is a former member of the Board of the New England Healthcare Institute (NEHI) and former Chairman of the Board of BioSymposia, an accredited provider of CME programs for medical scientists and healthcare professionals. He currently serves on ImmunoMet’s Board of Directors.

Scott Smith

In his most recent role at Celgene, Mr. Smith was the President and Chief Operating Officer where he was responsible for all key functions including Oncology Franchise Commercial Operations, Inflammation & Immunology Franchise Commercial Operations, Clinical Development, Regulatory Affairs and Manufacturing. Prior to that, Smith held the role of President, Inflammation & Immunology/Executive Vice President at Celgene and lead the charge in taking its lead candidate through proof of concept, clinical development, approval and global commercialization and established Inflammation & Immunology as a standalone franchise at Celgene. He was Vice President, Global Marketing before moving into these executive roles at Celgene.